Search results

Evidence-based recommendations on odevixibat (Bylvay) for treating progressive familial intrahepatic cholestasis in people 6 months and older

Type

Highly specialised technologies guidance

Published

22 February 2022

Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Type

Highly specialised technologies guidance

Published

05 May 2022

Evidence-based recommendations on givosiran (Givlaari) for treating acute hepatic porphyria in adults and young people aged 12 and over

Type

Highly specialised technologies guidance

Published

24 November 2021

Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies

Type

Highly specialised technologies guidance

Published

07 July 2021

Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages

Type

Highly specialised technologies guidance

Published

20 April 2022

Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children

Type

Highly specialised technologies guidance

Published

28 March 2022

Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms

Type

Medical technologies guidance

Published

20 May 2022

Evidence-based recommendations on Endo-SPONGE for treating low rectal anastomotic leak

Type

Medical technologies guidance

Published

16 December 2021

Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections

Type

Medical technologies guidance

Published

13 December 2021

Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers

Type

Medical technologies guidance

Published

07 March 2022

Evidence-based recommendations on Prontosan for treating acute and chronic wounds

Type

Medical technologies guidance

Published

08 March 2022

Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation

Type

Medical technologies guidance

Published

06 January 2022

Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography

Type

Medical technologies guidance

Published

04 October 2021

Evidence-based recommendations on Synergo for non-muscle-invasive bladder cancer

Type

Medical technologies guidance

Published

30 November 2021

Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure

Type

Medical technologies guidance

Last updated

21 July 2021

Evidence-based recommendations on myCOPD for managing chronic obstructive pulmonary disease

Type

Medical technologies guidance

Published

31 March 2022

Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections

Type

Medical technologies guidance

Published

31 March 2022

Evidence-based recommendations on Thopaz+ for managing chest drains

Type

Medical technologies guidance

Last updated

06 June 2022

Evidence-based recommendations on Peristeen Plus transanal irrigation system for managing bowel dysfunction

Type

Medical technologies guidance

Last updated

06 June 2022

Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care

Type

Medical technologies guidance

Published

27 January 2022

Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture

Type

Technology appraisal guidance

Published

25 May 2022

Evidence-based recommendations on risdiplam (Evrysdi) for 5q spinal muscular atrophy (SMA) in adults and children aged 2 months and over.

Type

Technology appraisal guidance

Published

16 December 2021

Evidence-based recommendations on fedratinib (Inrebic) for treating disease-related splenomegaly or symptoms in myelofibrosis in adults

Type

Technology appraisal guidance

Published

16 December 2021

Evidence-based recommendations on Palforzia for treating peanut allergy in children and young people

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMA

Type

Technology appraisal guidance

Published

14 July 2021

Evidence-based recommendations on chlormethine gel (Ledaga) for treating early-stage mycosis fungoides-type cutaneous T-cell lymphoma in adults

Type

Technology appraisal guidance

Published

18 August 2021

Evidence-based recommendations on abiraterone (Zytiga) for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer in adults

Type

Technology appraisal guidance

Published

18 August 2021

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation

Type

Technology appraisal guidance

Last updated

02 July 2021

Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus

Type

Technology appraisal guidance

Published

15 December 2021

Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug

Type

Technology appraisal guidance

Published

15 December 2021

Evidence-based recommendations on mogamulizumab (Poteligeo) for previously treated mycosis fungoides and Sézary syndrome in

Type

Technology appraisal guidance

Published

15 December 2021

Evidence-based recommendations on selpercatinib (Retsevmo) for previously treated RET fusion-positive advanced non-small-cell lung cancer in adults

Type

Technology appraisal guidance

Published

12 January 2022

Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by narcolepsy in adults

Type

Technology appraisal guidance

Published

05 January 2022

Evidence-based recommendations on fostamatinib (Tavlesse) for treating refractory chronic immune thrombocytopenia in adults

Type

Technology appraisal guidance

Published

07 January 2022

NICE is unable to make a recommendation on daratumumab (Darzalex) with bortezomib, melphalan and prednisone for untreated multiple myeloma because

Type

Technology appraisal guidance

Published

09 February 2022

Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults

Type

Technology appraisal guidance

Published

17 November 2021

Evidence-based recommendations on mexiletine (Namuscla) for treating the symptoms of myotonia in adults with non-dystrophic myotonic disorders

Type

Technology appraisal guidance

Published

01 December 2021

NICE is unable to make a recommendation on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after

Type

Technology appraisal guidance

Published

08 December 2021

NICE is unable to make a recommendation about the use in the NHS of isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple

Type

Technology appraisal guidance

Published

22 September 2021

NICE is unable to make a recommendation on liraglutide (Saxenda) for managing obesity in people aged 12 to 17 years because Novo Nordisk did not provide an

Type

Technology appraisal guidance

Published

01 December 2021

NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. This is because

Type

Technology appraisal guidance

Published

06 October 2021

Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults

Type

Technology appraisal guidance

Published

02 February 2022

NICE is unable to make a recommendation on olaparib (Lynparza) for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable

Type

Technology appraisal guidance

Published

02 February 2022

Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer

Type

Technology appraisal guidance

Published

09 February 2022

NICE is unable to make a recommendation on avapritinib (Ayvakit) for treating unresectable or metastatic gastrointestinal stromal tumours in adults because Blue

Type

Technology appraisal guidance

Published

29 September 2021